Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Randomized Study of Fluoxetine in Children and Adolescents With Autism
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development Mount Sinai Medical Center
|
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism. II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population. III. Compare the baseline compulsive severity and treatment outcome in these patients.
Condition | Treatment or Intervention |
---|---|
Autism |
Drug: fluoxetine |
MedlinePlus related topics: Autism
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment
Expected Total Enrollment: 50
Study start: September 1998
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study. All patients receive oral placebo daily during week 0. Patients are randomized to receive either oral fluoxetine or oral placebo daily on weeks 1-8. Patients then crossover to receive treatment on the other arm during weeks 12-20.
Eligibility
Ages Eligible for Study: 5 Years - 17 Years, Genders Eligible for Study: Both
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Meets diagnostic criteria for autism
--Prior/Concurrent Therapy--
Other:
--Patient Characteristics--
Hematopoietic: No significant hematopoietic disease
Hepatic: No prior or concurrent liver disease
Renal: No prior or concurrent kidney disease
Cardiovascular:
Neurological:
Other:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |